Clinical medicine profile
Fusidic acid / Hydrocortisone
Corticosteroid
- Route
- ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Systemic fungal infections (untreated) for systemic steroids.
- Live vaccines with significant immunosuppression.
- Hypersensitivity.
- Topical: untreated skin infection at site (relative).
Precautions
- [From component Hydrocortisone / Neomycin ear /eye drop] Warnings For external use only Do not use • in the genital area if you have a vaginal discharge.
- Consult a doctor. • for the treatment of diaper rash.
- Consult a doctor.
- When using this product • avoid contact with the eyes • do not use more than directed unless told to do so by a doctor • do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if • condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor • rectal bleeding occurs Keep out of reach of children.
- If swallowed, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Fluid retention/hypertension — care in renal disease.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Prednisone needs hepatic activation to prednisolone.
Use, effects & interactions
Indications
- Eczematous dermatoses when a secondary bacterial infection is present or suspected.
- Clinical selection for Fusidic acid / Hydrocortisone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Corticosteroid.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Insomnia, increased appetite, mood lability, dyspepsia, hyperglycaemia.
- Chronic: cushingoid features, myopathy, osteoporosis, HPA suppression.
- Topical: skin atrophy, striae.
- Inhaled: thrush, dysphonia.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Hydrocortisone / Neomycin ear /eye drop.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects.
Read complete mechanism
Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects. Mineralocorticoid activity varies by agent.
Hours–days
Agent and route dependent
ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
Pregnancy, lactation & diet
[Fusidic acid] Used when maternal benefit clear; prefer agents with better obstetric data (e.g. prednisolone). Document risk–benefit. [Hydrocortisone] Used when maternal benefit clear; prefer agents with better obstetric data (e.g. prednisolone). Document risk–benefit.
[Fusidic acid] Low-dose systemic often compatible; time feeds if high dose — agent-specific. [Hydrocortisone] Low-dose systemic often compatible; time feeds if high dose — agent-specific.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.